Anthem Biosciences IPO Overview

Anthem Biosciences IPO Overview

1. 📅 IPO Launch Date
Anthem Biosciences has scheduled its initial public offering (IPO) for August 7, 2025, aiming to raise growth capital and expand its R&D operations.

2. 💰 Offering Size & Price Range
They plan to offer 12 million shares, with an estimated price range of ₹350–₹380 per share. At midpoint, this could generate approximately ₹4.38 billion in fresh funds.

3. 🔍 Use of Proceeds
Raised capital is earmarked for:

• Enhancing R&D efforts, especially in gene and cell therapy platforms

• Scaling manufacturing capacity

• Funding regulatory filings globally

• General corporate purposes, including strategic expansion initiatives

4. 📈 Valuation & Market Context
At a mid-range price of ₹365/share, the IPO values Anthem Biosciences at around ₹48–₹50 billion (~$600M).
This places the company in a sensitive space—well above traditional smallcaps but not yet in the heavyweight biotech league.

5. 🧪 Company Highlights

• Pipeline strength: Multiple preclinical assets in oncology and rare diseases

• Strategic partnerships: Collaborations with multinational pharma companies for co-development

• Milestones achieved: Recent IND (Investigational New Drug) submission accepted by the US FDA in June 2025

6. 📊 Investment Considerations

• Upside potential: Institutional investment, strong pipeline could drive post-IPO momentum

• Sector volatility: Biotech IPOs often face sharp stock fluctuations based on trial updates

• Investment horizon: Ideal for those with a medium‑long term outlook, versus short-term traders

7. 🗓️ Important Dates

---

Why This IPO Matters 🧩

Anthem Biosciences stands at the forefront of India’s emerging biotech revolution. With global ambitions, a robust R&D pipeline, and an eye-catching market launch, it's poised to become a key player in the regional biotech ecosystem—and a compelling story for investors interested in innovation.